BIIB105 (ATXN2 ASO)
ALS
Key Facts
About Biogen
Founded in 1978, Biogen has established itself as a cornerstone of the biotechnology industry, renowned for pioneering multiple sclerosis treatments and launching the first approved therapy for Alzheimer's disease. The company's strategy is anchored in a focused R&D engine that reinvests approximately $2 billion annually into neurology, immunology, and rare disease pipelines, balancing bold scientific risk with disciplined capital allocation. Its mission is to translate cutting-edge science into transformative medicines, creating value for patients, shareholders, and communities.
View full company profileTherapeutic Areas
Other ALS Drugs
| Drug | Company | Phase |
|---|---|---|
| Stem Cell Program | BioArctic | Research |
| Eolo40 NCE | Eolo Pharma | Discovery |
| New targets program | Treeway | Preclinical |
| SYF2 Program | AcuraStem | Discovery |
| Target-03 | Verge Genomics | Discovery |
| Target-04 | Verge Genomics | Discovery |
| Undisclosed Program | BioArctic AB | Discovery |